Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy

Running, not enrolling · Not applicable

Conditions studied: Ovarian Carcinoma

In brief

This trial studies how well a diet high in magnesium works in preventing low blood magnesium levels (hypomagnesemia) in patients with ovarian cancer receiving carboplatin chemotherapy. Hypomagnesemia is a common side effect of carboplatin-containing chemotherapy. A magnesium rich diet may increase the levels of magnesium in the blood and help prevent hypomagnesemia resulting from carboplatin chemotherapy.

Key facts

Study ID

NCT04310826

Run by

M.D. Anderson Cancer Center

People needed

26

Starts

2019-04-23

Expected to finish

2026-04-01

Last updated by the study team

2026-02-17

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients with previously untreated ovarian cancer.
• Receiving carboplatin-containing chemotherapy of at least 6 consecutive cycles.
• Able to tolerate an oral diet.

You may not qualify if…

• Prior platinum-based chemotherapy.
• Serum creatinine level > 1.4 mg/dL prior to treatment.
• Artificial nutrition (e.g. Ensure or Boost) accounts for > 50% of total calorie intake.

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.